Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Immuron ( (IMRN) ) is now available.
On September 25, 2025, Immuron Limited announced the publication of its Appendix 4G and Corporate Governance Statement to the Australian Securities Exchange. This announcement highlights the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, reflecting its commitment to transparency and accountability. The release may impact stakeholders by reinforcing confidence in Immuron’s governance practices and potentially influencing investor perceptions positively.
The most recent analyst rating on (IMRN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Immuron stock, see the IMRN Stock Forecast page.
Spark’s Take on IMRN Stock
According to Spark, TipRanks’ AI Analyst, IMRN is a Neutral.
Immuron’s overall stock score is primarily impacted by its strong revenue growth yet significant challenges in profitability and cash flow, leading to liquidity concerns. The technical analysis presents a neutral outlook with slight downward pressure. The valuation remains unattractive due to a negative P/E ratio and no dividend yield, further weighing down the score.
To see Spark’s full report on IMRN stock, click here.
More about Immuron
Immuron Limited is an Australian company operating in the biotechnology industry, primarily focused on developing oral immunotherapy products. The company is known for its research and development in the field of infectious diseases and gastrointestinal health, targeting both human and animal health markets.
Average Trading Volume: 243,580
Technical Sentiment Signal: Sell
Current Market Cap: $13.14M
For a thorough assessment of IMRN stock, go to TipRanks’ Stock Analysis page.